French AI software developer Therapixel and Onsite Women's Health have entered into a partnership to deploy Therapixel's AI- platform, MammoScreen, across Onsite's provider network.
Onsite will offer MammoScreen across its more than 150 locations, the two firms said. It incorporates deep learning to help radiologists identify mammographic abnormalities that can be missed during manual review and has shown the ability to detect 42% of cancers one year prior to diagnosis and 38.5% two years prior, according to Therapixel.
Onsite was founded in 2008 and has performed more than two million exams across 26 states.
